This investigation evaluated the incidence, severity, and harm of adverse drug reactions (ADRs) associated with antipsychotic use for intensive care unit (ICU) delirium.
Methods:
In this prospective, observational study patients were screened for development of delirium with the Intensive Care Delirium Screening Checklist (ICDSC). An ICDSC score of ≥4 was considered delirious. Patients with delirium were screened daily for ADRs. Suspected ADRs were evaluated for drug causality using 3 published, objective assessment tools. Suspected ADRs were considered positive when 2 of 3 instruments had an agreement rating of “possible” or greater. ADR severity was defined as “mild/moderate” or “severe” using the National Cancer Institute’s Common Terminology Criteria for Adverse Events scale. A modified National Coordinating Council Medication Error Reporting Index for Categorizing Errors categorized ADRs into “no harm” or “harmful.”
Results:
Of 90 patients with delirium, 56 received antipsychotics. Ten suspected ADRs occurred attributed to antipsychotic use. QTc prolongation was the most observed ADR (50%). Patients with ADRs had higher mean Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (P = .038). Patients who received haloperidol experienced more severe (P = .048) ADRs.
Conclusions:
ADRs were observed in 18% of patients having delirium treated with antipsychotics with about half considered severe or harmful. A risk versus benefit assessment is needed before initiating antipsychotic therapy in ICU patients.
MilbrandtEBDeppenSHarrisonPL. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004;32(4):955–962.
2.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
3.
OuimetSKavanaghBPGottfriedSB. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med. 2007;33(1):66–73.
4.
American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.
5.
HippDMElyEW. Pharmacological and nonpharmacological management of delirium in cirtically ill patients. Neurotherapeutics. 2012;9(1):158–175.
6.
ElyEWShintaniATrumanB. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753–1762.
7.
GuntherMLMorandiAElyEW. Pathophysiology of delirium in the intensive care unit. Crit Care Clin. 2008;24(1):45–65.
8.
Van der MastRC. Pathophysiology of delirium. J Geriatr Psychiatry Neurol. 1998;11(3):138–145.
9.
PageVJElyEWGatesS. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2013;1(7):515–523.
10.
DevlinJWRobertsRJFongJJ. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med. 2010;38(2):419–427.
11.
GentileS. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy. 2013;33(10):1087–1106.
12.
ArmahizerMJSeybertALSmithburgerPL. Drug-drug interactions contributing to QT prolongation in the ICU. J Crit Care. 2013;28(3):243–249.
13.
SmithburgerPLSeybertALArmahizerMJ. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. Expert Opin Drug Saf. 2010;9(5):600–712.
14.
Kane-GillSLLeblancJLDastaJF. A multicenter study of the point-prevalence of drug-induced hypotension in the ICU. Crit Care Med. 2014;42(10):2197–2203.
15.
BergeronNDuboisMJDumontM. Intensive care delirium screening checklist: evaluation of a new screening tool. Intensive Care Med. 2001;27(5):859–864.
16.
PunBTGordonSMPetersonJF. Large-scale implementation of sedation and delirium monitoring in the intensive care unit: a report from two medical centers. Crit Care Med. 2005;33(6):1199–1205.
KramerMSLeventhalJMHutchinsonTA. An algorithm for the operational assessment of adverse drug reactions. I: Background, description, and instructions for use. JAMA. 1979;242(7):623–632.
19.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
20.
JonesJK. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Community Health. 1982;5(2):58–67.
21.
Kane-GillSLVisweswaranSSaulMI. Computerized detection of adverse drug reactions in the medical ICU. Int J Med Inform. 2011;80(8):570–578.
22.
HarinsteinLMKane-GillSLSmithburgerPL. Use of a laboratory-drug combination alert to detect drug-induced thrombocytopenia in critically ill patients. J Crit Care. 2012;27(3):242–249.
23.
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 4.0. National Institutes of Health, National Cancer Institute. May 28, 2009;4(03).
GirardTDPandharipandePPCarsonSS. Feasibility, efficacy, and safety of antipsychotics for ICU delirium: the MIND randomized, placebo-controlled trial. Crit Care Med. 2010;38(2):428–437.
26.
HuHDengWYangH. A prospective random control study comparison of olanzapine and haloperidol in senile delirium. Chongqing Med J. 2004;8:1234–1237.
27.
ManeetonBManeetonNSriurapanontM. Quetiapine versus haloperidol in the treatment of delirium: a double-blinded, randomized, controlled trial. Drug Des Devel Ther. 2013;7:657–667.
28.
LonerganEBrittonAMLuxenbergJ. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007;(2):CD005594.
29.
SkrobikYKBergeronNDumontM. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med. 2004;30(3):444–449.
30.
EdwardsIRAronsonJK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–1259.
31.
BreitbartWTremblayAGibsonC. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 2002;43(3):175–182.
32.
Kane-GillSLKirisciLVerricoMM. Identification of risk factors for adverse drug events in critically ill patients. Crit Care Med. 2012;40(3):823–828.
33.
RothschildJMLandriganCPCroninJW. The critical care safety study: the incidence and nature of adverse events and serious medical errors in intensive care. Crit Care Med. 2005;33(8):1694–1700.
34.
CullenDJSweitzerBJBatesDW. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997;25(8):1289–1297.
35.
BenkiraneRRR-AbouqalRHaimeurCC. Incidence of adverse drug events and medication errors in intensive care units: a prospective multicenter study. J Patient Saf. 2009;5(1):16–22.
36.
AnthesAMHarinsteinLMSmithburgerPL. Improvong adverse drug event detection in critically ill patients through screening intensive care unit transfer summaries. Pharmacoepidemiol Drug Saf. 2013;22(5):510–516.
37.
SmithburgerPLBuckleyMLLatI. Multi-center evaluation of ADRS due to off-label medication use in medical intensive care units. Crit Care Med. 2013;41(suppl 12):898.
